Current Document Type: HighlightsVideoPage Metastatic Breast Cancer Margetuximab Chemotherapy and Trastuzumab - JADPRO

Watch More Highlights

Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses the SOPHIA study, which APs need to be aware for their practice. The phase III trial compared margetuximab-cmkb plus chemotherapy (CTX) vs trastuzumab plus CTX in patients with HER2-positive metastatic breast cancer after prior anti-HER2 therapies (Abstract PD8-01).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.